I agree 100%. This stock is more than resilient. What amazing strength over the last two weeks on absolutely zero news. The accumulation for the past several months is very rare for a penny stock. This core is truly an unbelievable group of investors and will turn the general perception of the average retain investor on its head. Celts is a machine, an absolute hero here. Words cannot describe my appreciation for everything you've done for the core, including me and Team BSAV.
Below is a revised post that I published on iHub.
ScripsAmerica is in the middle of an impressive transformation. I expect many "wow" announcements over the next two quarters, each adding more support for the fundamentalists, technicians, and hybrids.
In less than a year we will know much more about where this company is heading. Indeed, I expect the PPS to hit $5 if the company fully succeeds on ALL of the following longterm goals:
1. Builds best-in-breed mini-McKesson business for the 20K-plus independent pharmacies and small retailers. This may include up to 6 sales reps selling for WholesaleRX and PIMD, each entity with class 2 licenses (minimum with 6 fully-functioning sales reps is about $2M monthly, $24M minimum annual run rate, $36M if all sales reps are rock stars and average $500K monthly).
2. Acquires more drug supply chain businesses and/or a larger ownership interest in WholesaleRX, thus further increasing the bottom line (presently 20%)(remember, we own 90% of PIMD, which is likely where Scrips will be focusing its sales staff as they continue to ramp up this low-risk business model).
3. Secures strong foothold in China with Children's RapiMed (only 5 days, 2 hours, and 7 minutes before regulatory approval), launches an improved RapiMed formula with IP protection, and expands its sales to many more formulations of RapiMed drug and vitamin products. Considering Children's RapiMed alone would generate about $27.5M annually with merely a quarter percent of the $11B Chinese pediatric OTC market in 2015, the potential for an expanded RapiMed brand maturing in the broader Chinese OTC, Rx and vitamin markets is immense.
4. Expands RapiMed brand to other large foreign markets (e.g., Europe, Latin America, Canada, South Africa, India). With the revenues from RapiMed China, Scrips will have vast resources to fund RapiMed launches elsewhere.
5. Successful RapiMed launch in the $1.4B U.S. pediatric OTC market with similar product improvements (of course, the same expansion opportunities of the RapiMed brand in exists in the U.S. market).
6. Per the Q&A...Enters compounding pharmacies business. (Guts has posted good info on this type of business.)
If Scrips hits a home run on just #1, we longs would have much to celebrate!
Good luck to all the current and future longs. More savvy investors are recognizing this amazing opportunity and adding SCRC to their portfolios. Indeed, Team BSAV today picked up another strong investor who made his first two buys totaling 150K shares at the end of the day. Earlier this week we picked up a small investment group that started to slowly accumulate shares. I have also talked to about five more people about Scrips this week, all of whom will one day be buyers of this stock. Eventually, I want all of my friends and family owning this stock and taking advantage of this fantastic opportunity.
Let's all get through next week and have another Friday close in the green to make it a Friday trifecta.
BSAV
Below is a revised post that I published on iHub.
ScripsAmerica is in the middle of an impressive transformation. I expect many "wow" announcements over the next two quarters, each adding more support for the fundamentalists, technicians, and hybrids.
In less than a year we will know much more about where this company is heading. Indeed, I expect the PPS to hit $5 if the company fully succeeds on ALL of the following longterm goals:
1. Builds best-in-breed mini-McKesson business for the 20K-plus independent pharmacies and small retailers. This may include up to 6 sales reps selling for WholesaleRX and PIMD, each entity with class 2 licenses (minimum with 6 fully-functioning sales reps is about $2M monthly, $24M minimum annual run rate, $36M if all sales reps are rock stars and average $500K monthly).
2. Acquires more drug supply chain businesses and/or a larger ownership interest in WholesaleRX, thus further increasing the bottom line (presently 20%)(remember, we own 90% of PIMD, which is likely where Scrips will be focusing its sales staff as they continue to ramp up this low-risk business model).
3. Secures strong foothold in China with Children's RapiMed (only 5 days, 2 hours, and 7 minutes before regulatory approval), launches an improved RapiMed formula with IP protection, and expands its sales to many more formulations of RapiMed drug and vitamin products. Considering Children's RapiMed alone would generate about $27.5M annually with merely a quarter percent of the $11B Chinese pediatric OTC market in 2015, the potential for an expanded RapiMed brand maturing in the broader Chinese OTC, Rx and vitamin markets is immense.
4. Expands RapiMed brand to other large foreign markets (e.g., Europe, Latin America, Canada, South Africa, India). With the revenues from RapiMed China, Scrips will have vast resources to fund RapiMed launches elsewhere.
5. Successful RapiMed launch in the $1.4B U.S. pediatric OTC market with similar product improvements (of course, the same expansion opportunities of the RapiMed brand in exists in the U.S. market).
6. Per the Q&A...Enters compounding pharmacies business. (Guts has posted good info on this type of business.)
If Scrips hits a home run on just #1, we longs would have much to celebrate!
Good luck to all the current and future longs. More savvy investors are recognizing this amazing opportunity and adding SCRC to their portfolios. Indeed, Team BSAV today picked up another strong investor who made his first two buys totaling 150K shares at the end of the day. Earlier this week we picked up a small investment group that started to slowly accumulate shares. I have also talked to about five more people about Scrips this week, all of whom will one day be buyers of this stock. Eventually, I want all of my friends and family owning this stock and taking advantage of this fantastic opportunity.
Let's all get through next week and have another Friday close in the green to make it a Friday trifecta.
BSAV
